{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:43:48Z","timestamp":1789267428693,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024J08304"],"award-info":[{"award-number":["2024J08304"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025J011418"],"award-info":[{"award-number":["2025J011418"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014125","name":"Fujian Provincial Health Commission","doi-asserted-by":"publisher","award":["2024GGB27"],"award-info":[{"award-number":["2024GGB27"]}],"id":[{"id":"10.13039\/501100014125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304629"],"award-info":[{"award-number":["82304629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z20254ZD1293"],"award-info":[{"award-number":["3502Z20254ZD1293"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202371048"],"award-info":[{"award-number":["3502Z202371048"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen City Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101106","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:50:13Z","timestamp":1768031413000},"page":"101106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study"],"prefix":"10.1016","volume":"46","author":[{"given":"Xiaorong","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-8155","authenticated-orcid":false,"given":"Wanlong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-8882","authenticated-orcid":false,"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctarc.2026.101106_bib0001","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101106_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101106_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101106_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122801","article-title":"Liposomes-enabled cancer chemoimmunotherapy","volume":"313","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101106_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101106_bib0006","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"33","key":"10.1016\/j.ctarc.2026.101106_bib0007","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101106_bib0008","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/jog.14680","article-title":"Hypersensitivity reaction to pegylated liposomal doxorubicin administration for mullerian carcinoma in Japanese women","volume":"47","author":"Yamaguchi","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101106_bib0009","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101106_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-023-01399-3","article-title":"Small molecule metabolites: discovery of biomarkers and therapeutic targets","volume":"8","author":"Qiu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101106_bib0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41579-021-00621-9","article-title":"Mass spectrometry-based metabolomics in microbiome investigations","volume":"20","author":"Bauermeister","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101106_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ctarc.2026.101106_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.04.012","article-title":"Metabolomics in breast cancer: a decade in review","volume":"67","author":"McCartney","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2026.101106_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1116806","article-title":"Association of serum metabolome profile with the risk of breast cancer in participants of the HUNT2 study","volume":"13","author":"Mrowiec","year":"2023","journal-title":"Front. Oncol."},{"issue":"42","key":"10.1016\/j.ctarc.2026.101106_bib0015","doi-asserted-by":"crossref","first-page":"28649","DOI":"10.1021\/acsnano.4c05087","article-title":"Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts","volume":"18","author":"Li","year":"2024","journal-title":"ACS. Nano"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101106_bib0016","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1021\/acsnano.2c12193","article-title":"Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines","volume":"17","author":"Chen","year":"2023","journal-title":"ACS. Nano"},{"issue":"2\u20133","key":"10.1016\/j.ctarc.2026.101106_bib0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101106_bib0018","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101106_bib0019","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1016\/j.cell.2023.09.020","article-title":"Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors","volume":"186","author":"Yadav","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101106_bib0020","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101106_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2023.112319","article-title":"Microbiota-derived tryptophan metabolism: impacts on health, aging, and disease","volume":"183","author":"Gupta","year":"2023","journal-title":"Exp. Gerontol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101106_bib0022","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.3390\/ijms25169040","article-title":"The Complex world of Kynurenic acid: reflections on biological issues and therapeutic strategy","volume":"25","author":"Stone","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101106_bib0023","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s11427-022-2296-0","article-title":"Phenylalanine diminishes M1 macrophage inflammation","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101106_bib0024","article-title":"A metabolic reprogramming amino acid polymer as an immunosurveillance activator and leukemia targeting drug carrier for T-cell acute lymphoblastic leukemia","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101106_bib0025","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/0026-0495(93)90131-7","article-title":"Phenylalanine conversion to tyrosine: comparative determination with L-[ring-2H5]phenylalanine and L-[1-13C]phenylalanine as tracers in man","volume":"42","author":"Marchini","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.ctarc.2026.101106_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.07.008","article-title":"Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses","volume":"94","author":"Sanchez-Blanco","year":"2018","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101106_bib0027","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1172\/JCI15719","article-title":"src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation","volume":"111","author":"Kamata","year":"2003","journal-title":"J. Clin. Invest."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:21:54Z","timestamp":1773969714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"alternative-id":["S2468294226000158"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101106","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101106"}}